- Home
- UTF vs IRON Comparison
UTF vs IRON Comparison
Compare UTF & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTF
- IRON
- Stock Information
- Founded
- UTF 2004
- IRON 2017
- Country
- UTF United States
- IRON United States
- Employees
- UTF N/A
- IRON N/A
- Industry
- UTF Finance Companies
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- UTF Finance
- IRON Health Care
- Exchange
- UTF Nasdaq
- IRON Nasdaq
- Market Cap
- UTF 2.4B
- IRON 2.1B
- IPO Year
- UTF N/A
- IRON N/A
- Fundamental
- Price
- UTF $24.75
- IRON $61.04
- Analyst Decision
- UTF
- IRON Strong Buy
- Analyst Count
- UTF 0
- IRON 10
- Target Price
- UTF N/A
- IRON $97.80
- AVG Volume (30 Days)
- UTF 171.7K
- IRON 290.0K
- Earning Date
- UTF 01-01-0001
- IRON 11-11-2025
- Dividend Yield
- UTF 7.19%
- IRON N/A
- EPS Growth
- UTF N/A
- IRON N/A
- EPS
- UTF 2.84
- IRON N/A
- Revenue
- UTF $138,636,669.00
- IRON N/A
- Revenue This Year
- UTF N/A
- IRON N/A
- Revenue Next Year
- UTF N/A
- IRON N/A
- P/E Ratio
- UTF $9.16
- IRON N/A
- Revenue Growth
- UTF 19.80
- IRON N/A
- 52 Week Low
- UTF $22.05
- IRON $30.82
- 52 Week High
- UTF $26.53
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- UTF 23.10
- IRON 56.19
- Support Level
- UTF $24.52
- IRON $58.36
- Resistance Level
- UTF $26.17
- IRON $61.27
- Average True Range (ATR)
- UTF 0.31
- IRON 2.35
- MACD
- UTF -0.18
- IRON -0.10
- Stochastic Oscillator
- UTF 10.31
- IRON 38.82
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.